Yuhan-Kimberly, a joint venture between Korea’s Yuhan Corp. and America’s Kimberly Clark, has been chosen as one of the ...

SEOUL, Oct. 28 (Yonhap) -- Yuhan Corp., a South Korean biopharmaceutical company, said Monday its third-quarter net profit ...

Yuhan Corporation CEO Wook Je Cho, National Assembly Member Seong Hoon Park, and KAIST Professor Joung Ho Kim join a ...

Singer and actress IU is fighting against the haters. Among the malicious comments under criminal complaint, a person ...

Gilead Sciences has abandoned a liver disease collaboration with Yuhan. A new study suggests Leqembi's vial design could cost Medicare hundreds of millions of dollars in waste each year.

Reporting in the journal Nature, Caltech-led researchers have uncovered where FRBs are more likely to occur in the ...

The rising prevalence of urticaria is fueling market growth, with increased allergic responses and lifestyle shifts playing key roles. Advances in biologic treatments and a strong development pipeline ...

In terms of improving the wellbeing of all mankind, China and the US should give full play to their respective advantages and ...

Designed to provide broad exposure to the Broad Developed World ETFs category of the market, the JPMorgan Diversified Return International Equity ETF (JPIN) is a smart beta exchange traded fund ...

Gilead Sciences Inc. terminated a potential $785 million licensing deal with Yuhan Corp. inked in 2019 to develop metabolic dysfunction-associated steatohepatitis (MASH) therapies. BioWorld Asia Deals ...